|
News
Phoenix Scientific, Inc. Announces
Investment in CritiTech, Inc.
September 30, 2004
FOR IMMEDIATE RELEASE
St. Joseph, Missouri-Phoenix Scientific,
Inc. announced today that it has made a significant financial
investment in CritiTech Inc., Lawrence, Kansas. CritiTech
provides drug delivery and development technology for the
pharmaceutical industry. CritiTech produces fine particle
pharmaceuticals including nanoparticle pharmaceuticals using
patented technologies developed at the University of Kansas.
The processes use compressed carbon dioxide as the processing
medium to produce relatively residue-free and uniform drug
microparticles and coatings. Sam Campbell, President of CritiTech
stated, “We are extremely pleased to have the support
of such an outstanding company as Phoenix Scientific and its
impressive management team. Through this relationship we believe
Phoenix Scientific will enhance its position as the leading
developer of veterinary therapeutics. We are looking forward
to a long and mutually beneficial relationship.”
Phoenix Scientific, located in St. Joseph,
Missouri, is the United States’ largest manufacturer
of veterinary pharmaceutical formulations and the leader in
differentiated generic animal health pharmaceutical products.
Phoenix Scientific will have the exclusive first right of
refusal for any drug technology with applications in the veterinary
pharmaceutical industry developed by CritiTech. Kevin Schinze,
President and CEO of Phoenix stated “The investment
in CritiTech provides Phoenix with another foundation for
improving formulations and enabling with delivery of poorly
soluble compounds. CritiTech is on the cutting edge of some
very promising technology and we hope to bring these processes
to veterinary medicine.”
|
